Press Releases

Precision BioLogic’s Factor VIII Deficient Plasma with VWF Now FDA-Cleared for Sale in U.S.

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of our new cryocheck™ Factor VIII Deficient Plasma with VWF in the U.S. The latest in Precision BioLogic’s family of factor deficient plasmas, cryocheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A. It has normal levels of von Willebrand factor (VWF) but both FVIII antigen and activity levels of less than 1%. The importance of FVIII antigen levels in the performance of FVIII deficient substrates was demonstrated in a study presented at ISTH 2021. "CRYOcheck Factor VIII Deficient Plasma with VWF offers labs a readily available and reliable alternative to congenital FVIII deficient plasmas. In fact, the product has already gained significant traction within the hemophilia research and pharmaceutical manufacturing community," says Paul Empey, President & CEO of Precision BioLogic.

PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services

Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications.

BioIVT Webinar Will Discuss How to Manage Uncooperative Drugs in In Vitro Transporter Research

Dr. Joanna Barbara will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.

AVIA Launches Innovative AI Labs, AI Co-pilot for Digital Health Transformation

AVIA's newest AI-focused initiative aims to share practical application of AI to better inform - and transform - the healthcare industry

Alfa Chemistry Unveils Revitalized Strong/Weak Acid Cation Resin and Base Anion Resin Lineup

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems

Daptomycin ReadyMade™ Solution to Power Up Spectrum and Microbiology Applications

SMi Systems secures UK patent for breakthrough single molecule imaging capabilities

SMi Systems has secured a patent from the UK Intellectual Property Office for the single-molecule imaging technologies that underpin its super-resolution multi-omic platform.

ELRIG UK Establishes Engagement Strategy Work Group

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the formation of its Engagement Strategy Work Group (ESWG). The group will provide strategic direction and guidance to help ensure the ELRIG community continues to grow and thrive. It aims to engage audiences in different ways, beyond face-to-face events, broadening access to high-quality science across a more diverse and inclusive network.

Huateng Pharma to Attend CPHI Barcelona 2023

Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.

Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced the availability of a new Neurodevelopmental Disorders Panel for children and other patients affected by a suspected or clinically diagnosed autism spectrum disorder, intellectual disability, and/or developmental delay. The panel analyzes a clinically curated and targeted set of 236 genes to help healthcare providers and patients achieve a prompt, accurate genetic diagnosis and a better understanding of prognosis and anticipated disease progression.

PathAI Launches AISight™ Link to Support Integration Solutions for Laboratory Customers and Biopharma Partners

PathAI, a leading provider of precision pathology solutions, today announced that its recently launched image management system, AISight, is now available with a full suite of integration solutions, called AISight Link, to meet the needs of various customer segments across the digital pathology ecosystem.

Amerigo Scientific Releases FSB Solution Products to Expedite Alzheimer’s Disease Research

AVIA’s National Generative AI Collaborative Announces New Experts, Enhanced Health System Participation

The Generative AI Strategic Collaborative reveals a slate of 10 clinical, ethics, technology, and regulatory experts for its national consortium

BioIVT Completes XenoTech Integration, Highlights Expanded ADME-Tox Research Services at the North American ISSX Meeting

BioIVT has implemented new tiered ‘fit-for-purpose’ study designs for metabolism, drug-drug interaction, and transporter programs. This approach takes advantage of their electronic notebook system and automated reports, enabling them to better meet clients’ needs by reducing turnaround time, while maintaining the highest level of scientific expertise and quality.

GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting

GenNext Technologies, Inc. has announced the release of the AutoFox Protein Footprinting System at the California Separation Science Society combined Mass Spectrometry and Higher Order Structure meetings.

iotaSciences and Quantum Design China Enter into Distribution Agreement

iotaSciences and Quantum Design China announced today an exclusive distribution agreement for iotaSciences proprietary single cell handling platforms in China.

GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical Research

GenNext Technologies, Inc. has revealed their agreement to co-market a robust, full-solution workflow for Hydroxyl Radical Protein Footprinting studies with SCIEX.